COMPANY
OVERVIEW
Nu Eyne aims to become a world-class global medical technology R&D company by driving technological innovation and transforming the paradigm of healthcare in a field where the Korean medical device industry has traditionally faced significant challenges.
We are particularly focused on addressing diseases that are difficult to treat with existing therapies, thereby contributing to the improvement of human health and well-being.
Nu Eyne leads the next generation of medical technology—Bioelectronic Medicine.
2026
Q1 ADDNOX designated as a Breakthrough Medical Device by K-MFDS
Q1 Published SCI paper on exploratory clinical study for ASD patients (Nature Reviews)
Q2 Received IND approval for exploratory clinical trial of RTN 002 in patients with dry age-related macular degeneration (AMD)
2025
Q1 Launched WITHNOX - a consumer healthcare product for sleep and focus
Q3 SMILE, ADHD treatment device, cleared under the special permit and launched in Hainan, China
2024
Q2 Dong-A PharmaceuRanked No. 1 in the Electroceuticals Category at the 2024 Brand Customer Loyalty Awards
Q2 tical launched Nu Eyne's migraine treatment device in Korea
Q4 Local launch of migraine treatment device in Thailand
2023
Q1 Obtained U.S. FDA clearance for ADHD treatment device
Q2 Signed an exclusive domestic supply agreement with Dong-A Pharmaceutical for the migraine treatment device
Q2 Published SCI paper on exploratory clinical study for dry eye disease patients (Ophthalmology Science)
Q2 Received IND approval for confirmatory dry eye clinical trial (DED 003)
Q3 Registered patent for Technology in Adjunctive Cancer Therapy
Awards: Korea Good Company Grand Prize MEDITECH Innovation Best Award
Q4 Selected as a 2023 Hi-Seoul Company
2022
Q2 Received IND approval for exploratory clinical trial of RTN 001 in patients with dry age-related macular degeneration (AMD)
Q3 Received IND approval for exploratory electrical stimulation clinical trial in patients with Autism Spectrum Disorder (ASD)
Q4 Launched migraine treatment device "ELEXIR" in Thailand
Q4 Won DESIGN iT Award 2022 – Bronze Prize
2021
Q1 Obtained regulatory approvals for migraine treatment device in the United States and Canada
Q1 Received IND approval for investigator-initiated dry eye clinical trial (DED 002)
Q1 Received IND approval for retinal exploratory clinical trial (RTN 001)
Q3 Obtained multiple government certifications Received commendations from: Minister of Health and Welfare / Minister of Trade, Industry and Energy
Q4 Completed Series C fundraising
2020
Q1 Received IND approval for exploratory dry eye clinical trial (DED 001)
Q2 Obtained European CE MDD certification for migraine treatment device
Q4 Obtained MDSAP certification covering medical device manufacturing for five countries
Q4 Selected as the top company in Seoul City's Stage Eureka Program (Smart Safety & Healthcare Sector)
2019
Q2 Signed MOU between Nu Eyne and the Biomedical Engineering Center of Samsung Medical Center
Q3 Obtained GMP certification for medical device manufacturing
Q4 Grand Winner of the UK Tech Rocketship Awards
Q4 Completed Series B fundraising
2018
Q1 Samsung Medical Center and Nu Eyne initiated joint preclinical animal studies
Q2 Published technical paper related to implantable electrical stimulation devices
Q3 Completed Series A fundraising
2017
Q3 Founded Nu Eyne Co., Ltd.
Q3 Secured Seed Fund investment
Q4 Winner of the Johnson & Johnson Global Medical Technology Startup Competition
Nu Eyne aims to become a world-class global medical technology R&D company by driving technological innovation and transforming the paradigm of healthcare in a field where the Korean medical device industry has traditionally faced significant challenges.
We are particularly focused on addressing diseases that are difficult to treat with existing therapies, thereby contributing to the improvement of human health and well-being.
Nu Eyne leads the next generation of medical technology—Bioelectronic Medicine.
2026
| Q1 | ADDNOX designated as a Breakthrough Medical Device by K-MFDS |
| Q1 | Published SCI paper on exploratory clinical study for ASD patients (Nature Reviews) |
| Q2 | Received IND approval for exploratory clinical trial of RTN 002 in patients with dry age-related macular degeneration (AMD) |
2025
| Q1 | Launched WITHNOX - a consumer healthcare product for sleep and focus |
| Q3 | SMILE, ADHD treatment device, cleared under the special permit and launched in Hainan, China |
2024
| Q2 | Dong-A PharmaceuRanked No. 1 in the Electroceuticals Category at the 2024 Brand Customer Loyalty Awards |
| Q2 | tical launched Nu Eyne's migraine treatment device in Korea |
| Q4 | Local launch of migraine treatment device in Thailand |
2023
| Q1 | Obtained U.S. FDA clearance for ADHD treatment device |
| Q2 | Signed an exclusive domestic supply agreement with Dong-A Pharmaceutical for the migraine treatment device |
| Q2 | Published SCI paper on exploratory clinical study for dry eye disease patients (Ophthalmology Science) |
| Q2 | Received IND approval for confirmatory dry eye clinical trial (DED 003) |
| Q3 | Registered patent for Technology in Adjunctive Cancer Therapy Awards: Korea Good Company Grand Prize / MEDITECH Innovation Best Award |
| Q4 | Selected as a 2023 Hi-Seoul Company |
2022
| Q2 | Received IND approval for exploratory clinical trial of RTN 001 in patients with dry age-related macular degeneration (AMD) |
| Q3 | Received IND approval for exploratory electrical stimulation clinical trial in patients with Autism Spectrum Disorder (ASD) |
| Q4 | Launched migraine treatment device "ELEXIR" in Thailand |
| Q4 | Won DESIGN iT Award 2022 – Bronze Prize |
2021
| Q1 | Obtained regulatory approvals for migraine treatment device in the United States and Canada |
| Q1 | Received IND approval for investigator-initiated dry eye clinical trial (DED 002) |
| Q1 | Received IND approval for retinal exploratory clinical trial (RTN 001) |
| Q3 | Obtained multiple government certifications Received commendations from: Minister of Health and Welfare / Minister of Trade, Industry and Energy |
| Q4 | Completed Series C fundraising |
2020
| Q1 | Received IND approval for exploratory dry eye clinical trial (DED 001) |
| Q2 | Obtained European CE MDD certification for migraine treatment device |
| Q4 | Obtained MDSAP certification covering medical device manufacturing for five countries |
| Q4 | Selected as the top company in Seoul City's Stage Eureka Program (Smart Safety & Healthcare Sector) |
2019
| Q2 | Signed MOU between Nu Eyne and the Biomedical Engineering Center of Samsung Medical Center |
| Q3 | Obtained GMP certification for medical device manufacturing |
| Q4 | Grand Winner of the UK Tech Rocketship Awards |
| Q4 | Completed Series B fundraising |
2018
| Q1 | Samsung Medical Center and Nu Eyne initiated joint preclinical animal studies |
| Q2 | Published technical paper related to implantable electrical stimulation devices |
| Q3 | Completed Series A fundraising |
2017
| Q3 | Founded Nu Eyne Co., Ltd. |
| Q3 | Secured Seed Fund investment |
| Q4 | Winner of the Johnson & Johnson Global Medical Technology Startup Competition |
